Variable severity and Ia antigen expression in streptococcal-cell-wall-induced hepatic granulomas in rats.
We have previously reported that a single intraperitoneal injection of an aqueous suspension of group A streptococcal cell wall (SCW) fragments induces extensive hepatic granulomas in LEW/N female rats, but not in F344/N female rats. To further understand the mechanisms underlying these differences, we compared granuloma development and class II major histocompatibility complex antigen (Ia) expression in histocompatible LEW/N, F344/N, and CAR/N female rats in response to SCW fragments of four different average molecular sizes. In LEW/N female rats, the smallest fragments (less than 5 megadaltons) induced the most severe hepatic inflammatory disease, with development of widespread granulomas composed of macrophages, lymphocytes, and a peripheral rim of fibroblasts. The largest fragments (greater than 500 megadaltons) induced equivocal disease. Fragments of intermediate size induced granulomas of intermediate severity. The extent of granuloma development, the intensity of Ia antigen expression, and the amount of SCW antigen deposited in the liver qualitatively paralleled each other. In contrast, injection of the most granulomagenic SCW fragments into F344/N and CAR/N rats did not induce granulomas. Although these rat strains are histocompatible with the LEW/N (i.e., RTL.1) strain, hepatic Ia antigen expression in these strains was not increased significantly above basal levels. The amount of SCW antigen in the livers of the resistant rat strains appeared similar to the amount in the susceptible LEW/N strain. These data indicate that granuloma development is dependent on the size of the SCW fragment and host genetic background and that Ia expression directly parallels the severity of the hepatic disease. In addition, the data suggest that non-major histocompatibility complex genetic loci play a major role in regulating the development of the hepatic disease.
D000818:Animals; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000633:toxicity*; D002473:Cell Wall / Q000276:immunology; D005260:Female; D006099:Granuloma / Q000209:etiology / Q000276:immunology / Q000473:pathology*; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D007249:Inflammation; D007274:Injections, Intraperitoneal; D008107:Liver Diseases / Q000209:etiology / Q000276:immunology / Q000473:pathology*; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D013297:Streptococcus pyogenes / Q000276:immunology*
D000942:Antigens, Bacterial; D000949:Histocompatibility Antigens Class II